Catalog No.
DHE43207
Expression system
Mammalian Cells
Species reactivity
Human
Host species
Human
Isotype
IgG1-kappa
Clonality
Monoclonal
Target
ACT35 antigen, TXGP1L, TAX transcriptionally-activated glycoprotein 1 receptor, Tumor necrosis factor receptor superfamily member 4, TNFRSF4, OX40L receptor, CD134
Concentration
1.12 mg/ml
Endotoxin level
Please contact with the lab for this information.
Purity
>95% as determined by SDS-PAGE.
Purification
Protein A/G purified from cell culture supernatant.
Accession
P43489
Applications
Research Grade Biosimilar
Form
Liquid
Storage buffer
0.01M PBS, pH 7.4.
Stability and Storage
Use a manual defrost freezer and avoid repeated freeze-thaw cycles. Store at 4°C short term (1-2 weeks). Store at -20°C 12 months. Store at -80°C long term.
Alternative Names
KHK 4083, KHK-4083, KHK4083 CAS: 2431972-52-8
Clone ID
Rocatinlimab
Emerging Therapies in the Treatment of Prurigo Nodularis: Biological Therapy and Systematic Review of Literature., PMID:40372666
OX40/OX40L as a Therapeutic Target in Atopic Dermatitis: A Scoping Review., PMID:40331215
Safety and Efficacy of Anti-OX40 Therapies in Atopic Dermatitis: A Systematic Review and Meta-Analysis., PMID:40229131
Investigating Efficacy of Atopic Dermatitis Systemic Therapeutics After Discontinuation Part I: Biologics., PMID:40078859
ROCKET: a phase 3 program evaluating the efficacy and safety of rocatinlimab in moderate-to-severe atopic dermatitis., PMID:40012373
Ritlecitinib, a JAK3 /TEC inhibitor, modulates the markers of celiac autoimmunity in alopecia areata and vitiligo patients., PMID:39825945
A Narrative Review of the OX40-OX40L Pathway as a Potential Therapeutic Target in Atopic Dermatitis: Focus on Rocatinlimab and Amlitelimab., PMID:39565527
Rocatinlimab Improves Patient-Reported Outcomes in Adults with Moderate-to-Severe Atopic Dermatitis: Results from a Double-Blind Placebo-Controlled Phase 2b Study., PMID:39532780
Durable improvements in atopic dermatitis in the head and neck and across other anatomic regions with rocatinlimab., PMID:39503757
Decoupling the association of dupilumab with cutaneous T-cell lymphoma., PMID:39251029
Biologic and Small Molecule Therapy in Atopic Dermatitis., PMID:39200305
A Comprehensive Review of Biologics in Phase III and IV Clinical Trials for Atopic Dermatitis., PMID:39064040
Hands-on: a novel JAK inhibitor for the treatment of chronic hand eczema., PMID:39033765
Emerging drugs for the treatment of atopic dermatitis: a focus on phase 2 and phase 3 trials., PMID:38662529
OX40 in the Pathogenesis of Atopic Dermatitis-A New Therapeutic Target., PMID:38236520
Summary of Research: An Anti-OX40 Antibody to Treat Moderate-to-Severe Atopic Dermatitis: A Multicentre, Double-Blind, Placebo-Controlled Phase 2b Study., PMID:38185777
An overview of new and emerging antibody therapies for moderate-severe atopic dermatitis in adults., PMID:38054328
Efficacy of rocatinlimab for moderate-to-severe atopic dermatitis - Authors' reply., PMID:37980090
Efficacy of rocatinlimab for moderate-to-severe atopic dermatitis., PMID:37980089
OX40-OX40L Inhibition for the Treatment of Atopic Dermatitis-Focus on Rocatinlimab and Amlitelimab., PMID:36559247
An anti-OX40 antibody to treat moderate-to-severe atopic dermatitis: a multicentre, double-blind, placebo-controlled phase 2b study., PMID:36509097
For research use only. Not for human or drug use.
